Carbapenemase_producing_K__pneumoniae__ST258_

This study is to better understand the molecular epidemiology of an outbreak of a carbapenemase-producing Klebsiella pneumoniae ST258 in a tertiary hospital setting. This outbreak involves a novel variant of K. pneumoniae ST258, which is recognised internationally as a high-risk clone (HiRiC) and has established outbreak potential, and is capable of national spread. The novel variant produces two different carbapenemases and has enhanced antimicrobial resistance; it is resistant even to the newly-licensed agent ceftazidime-avibactam, ruling out a further treatment option. Understanding the molecular characteristics of these strains is crucial to prevent onward spread, for directing resources, predictive antimicrobial sensitivity and surveillance reporting.